ELUT
HEALTHCAREElutia Inc - Class A
$1.02+0.04 (+4.54%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ELUT Today?
No stock-specific AI insight has been generated for ELUT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.50$2.64
$1.02
Fundamentals
Market Cap$47M
P/E Ratio—
EPS$-0.64
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin4.3%
Debt / Equity—
Trading
Volume224K
Avg Volume (10D)—
Shares Outstanding44.2M
ELUT News
20 articles- TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesYahoo Finance·Apr 30, 2026
- Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026Yahoo Finance·Apr 30, 2026
- Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19Yahoo Finance·Mar 17, 2026
- Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 13, 2026
- Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ...Yahoo Finance·Mar 12, 2026
- Elutia Inc. Q4 2025 Earnings Call SummaryMoby·Mar 12, 2026
- Elutia (ELUT) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 11, 2026
- Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory ProcessYahoo Finance·Mar 11, 2026
- Elutia Regains Compliance with Nasdaq Listing RequirementsYahoo Finance·Mar 4, 2026
- Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery MarketYahoo Finance·Mar 2, 2026
- Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026Yahoo Finance·Feb 25, 2026
- Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™Yahoo Finance·Feb 18, 2026
- Insider Spends US$74k Buying More Shares In ElutiaYahoo Finance·Feb 4, 2026
- Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x MilestonesYahoo Finance·Jan 12, 2026
- Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive SurgeryYahoo Finance·Jan 9, 2026
- ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Dec 31, 2025
- How The BioEnvelope Sale Is Changing Elutia’s Story and Shaping Its Future ValuationYahoo Finance·Dec 2, 2025
- M&A Strategy Strengthens Boston Scientific's Growth ProspectsYahoo Finance·Dec 2, 2025
- Why Analysts See a Shifting Story for Elutia After the BioEnvelope SaleYahoo Finance·Nov 18, 2025
- Elutia Inc (ELUT) Q3 2025 Earnings Call Highlights: Strategic Growth and Financial ResilienceYahoo Finance·Nov 7, 2025
All 20 articles loaded
Price Data
Open$1.04
Previous Close$0.98
Day High$1.05
Day Low$0.95
52 Week High$2.64
52 Week Low$0.50
52-Week Range
$0.50$2.64
$1.02
Fundamentals
Market Cap$47M
P/E Ratio—
EPS$-0.64
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin4.3%
Debt / Equity—
Trading
Volume224K
Avg Volume (10D)—
Shares Outstanding44.2M
About Elutia Inc - Class A
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—